A-Alpha Bio - About the company
A-Alpha Bio is a series A company based in Seattle (United States), founded in 2017 by Randolph Lopez and David Younger. It operates as a Developer of cell-based tool for the measurements of protein interactions. A-Alpha Bio has raised $45.2M in funding from investors like Madrona, OS Fund and Xontogeny. The company has 172 active competitors, including 31 funded and 28 that have exited. Its top competitors include companies like Nautilus Biotechnology, Somalogic and Biognosys.
Company Details
Developer of cell-based tool for the measurements of protein interactions. The company offers cell-based platform technology that measures protein interactions with the help of engineered yeast cells. It enhances drug development by measuring protein interactions.
- Website
- www.aalphabio.com/
- Social
- Email ID
- *****@aalphabio.com
Key Metrics
Founded Year
2017
Location
Seattle, United States
Stage
Series A
Total Funding
$45.2M in 10 rounds
Latest Funding Round
Ranked
5th among 172 active competitors
Employee Count
49 as on Mar 31, 2026
Similar Companies
Legal entities associated with A-Alpha Bio
A-Alpha Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
A-alpha Bio, Inc. CIN: 823070666 , United States, Active | Dec 31, 1999 | - | 48 (As on Dec 31, 2024) | - |
Sign up to download A-Alpha Bio's company profile
A-Alpha Bio's funding and investors
A-Alpha Bio has raised a total funding of $45.2M over 10 rounds. Its first funding round was on Jul 01, 2018. Its latest funding round was a Grant (prize money) round on May 21, 2024 for $*****. 1 investor participated in its latest round. A-Alpha Bio has 17 institutional investors.
Here is the list of recent funding rounds of A-Alpha Bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 21, 2024 | 3753226 | Grant (prize money) | 4702724 | 8822755 | 9920417 | 4469728 |
Jul 25, 2023 | 6294063 | Series A | 6648834 | 8145377 | 8239133 | |
May 2023 | 7248105 | Grant (prize money) | 1343699 | 6872983 | 7451729 |
Access funding benchmarks and valuations. Sign up today!View details of A-Alpha Bio's funding rounds and investors
A-Alpha Bio's founders and board of directors
Founder? Claim ProfileThe founders of A-Alpha Bio are Randolph Lopez and David Younger.
Here are the details of A-Alpha Bio's key team members:
- Randolph Lopez: Co-founder & CTO of A-Alpha Bio. Contact Info: 1 email address
- David Younger: Founder & CEO of A-Alpha Bio. Contact Info: 1 email address
A-Alpha Bio's Board of Directors
A-Alpha Bio's board has 4 active members. Matt Mcilwain, David Younger, Ben Askew and Randolph Lopez Barrezueta are independent board members.Here is the list of A-Alpha Bio's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Independent board member | - | Current | 4y 6m | |
qasbryo | Independent board member | - | Current | 2y 2m |
be{oe{w | Independent board member | - | Current | 2y 8m |
olbudml | Independent board member | - | Current | 2y 2m |
View details of A-Alpha Bio's Founder profiles and Board Members
A-Alpha Bio's employee count trend
A-Alpha Bio has 49 employees as of Mar 26. Here is A-Alpha Bio's employee count trend over the years:
Uncover A-Alpha Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
A-Alpha Bio's Competitors and alternates
Top competitors of A-Alpha Bio include Nautilus Biotechnology, Somalogic and Biognosys. Here is the list of Top 10 competitors of A-Alpha Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nautilus Biotechnology 2016, Seattle (United States), Public | Developer of proteomics platform for drug development | $453M | 65/100 | |
2nd | Somalogic 1999, Boulder (United States), Acquired | Developer of protein-based assays for life science research | $664M | 64/100 | |
3rd | Biognosys 2008, Schlieren (Switzerland), Acquired | Provider of proteomics service | $9.13M | 63/100 | |
4th | Arzeda 2008, Seattle (United States), Series B | Developer of enzyme design technology to bridge the gap by creating synthetic enzymes | $95.2M | 58/100 | |
5th | A-Alpha Bio 2017, Seattle (United States), Series A | Developer of cell-based tool for the measurements of protein interactions | $45.2M | 56/100 | |
6th | ProteinSimple 2004, San Jose (United States), Acquired | Provider tools to help researchers with protein analysis | $94.3M | 57/100 | |
7th | Amunix 2006, Mountain View (United States), Acquired | Developer of peptide-based therapeutics | $201M | 57/100 | |
8th | Dynamic Biosensors 2011, Planegg (Germany), Acquired | Provides solutions for label-free molecular interaction and biophysical analysis | $5.83M | 56/100 | |
9th | Mursla 2017, London (United Kingdom), Seed | Provider of diagnostic device for cancer detection | $547K | 55/100 | |
10th | Cevec Pharmaceuticals 2001, Cologne (Germany), Acquired | Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28.4M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on A-Alpha Bio's competitors? Click here to see the top ones
A-Alpha Bio's Investments and acquisitions
A-Alpha Bio has made no investments or acquisitions yet.
News related to A-Alpha Bio
Filter this listMedia has covered A-Alpha Bio for 1 event in last 1 year, It was about people movement.
•
A-Alpha Bio Appoints Troy Lionberger as Chief Business Officer for GrowthGlobeNewswire•Sep 23, 2025•A-Alpha Bio
•
•
•
•
•
•
A-Alpha Bio lands $2.4M from DOD for antibody discovery projectThe Business Journals•May 17, 2023•A-Alpha Bio
•
•
BMS protein degradation drug research turns to a startup to find molecular gluesMedCity News•Aug 24, 2022•Bristol-Myers Squibb, A-Alpha Bio
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about A-Alpha Bio
Explore our recently published companies
- Sciom.com - 2003 founded, Unfunded company
- Kagulex - Horsham based, 2023 founded, Unfunded company
- Mrigangi - 2018 founded, Unfunded company
- Foxypearljewelry - Houston based, 2020 founded, Unfunded company
- ThunderBurst Media - Dallas based, 2021 founded, Unfunded company
- Ekuom - Shanghai based, Unfunded company
